TNGX - Tango Therapeutics, Inc.

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today reported financial results for the first quarter ended March 31, 2026, and provided business highlights. “We continue to work diligently to advance vopimetostat towards pivotal development in pancreatic cancer and remain highly encouraged by the potential of the ongoing study of vopimetostat in combination with RAS(ON) inhibitors,” said Malte Peters, M.D.

May 13, 2026 12:07 PM • globenewswire.com

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option to purchase an aggregate of 240,000 shares of its common stock and 40,000 restricted stock units (RSUs) to Matthew Gall, the Company's Chief Financial Officer and (ii) a non-qualified stock option to purchase an aggregate of 199,650 shares of its common stock and 33,250 RSUs to a new employee, under Tango Therapeutics' 2023 Inducement Plan.

May 04, 2026 12:31 PM • globenewswire.com

Massachusetts Financial Services Co. MA Acquires New Shares in Tango Therapeutics, Inc. $TNGX

Massachusetts Financial Services Co. MA acquired a new stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,023 shares of the company's stock, valued at approximately $248,000. A number of other large investors have

Apr 19, 2026 12:58 AM • defenseworld.net

Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $961,500.00 in Stock

Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) insider Adam Crystal sold 38,460 shares of Tango Therapeutics stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $25.00, for a total value of $961,500.00. Following the completion of the sale, the insider owned 112,622 shares in the company,

Apr 19, 2026 12:22 AM • defenseworld.net

Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat

-  Matthew Gall appointed Chief Financial Officer  - -  Additional key appointments add expertise in clinical operations, corporate strategy and project leadership  -

Apr 15, 2026 05:05 AM • globenewswire.com

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

27,000 common shares were sold via option exercise on April 1, 2026, generating proceeds of approximately $572,000 at a weighted average of $21.20 per share. The transaction reduced Adam's direct common stock position from 139,622 to 112,622 shares -- a reduction of 19.34% of her pre-sale holdings.

Apr 08, 2026 05:52 AM • fool.com

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

Adam Crystal sold 20,251 shares for a transaction value of ~$304,000 on March 5, 2026, at an average price of around $15 per share. This sale represented 15.24% of Crystal's direct holdings, reducing his directly held position from 132,873 to 112,622 shares.

Mar 30, 2026 09:33 AM • fool.com

Adam Crystal Sells 12,000 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock

Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) insider Adam Crystal sold 12,000 shares of the firm's stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $20.11, for a total value of $241,320.00. Following the completion of the transaction, the insider directly owned 112,622 shares of the

Mar 28, 2026 12:29 AM • defenseworld.net

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider. com News Commentary - Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financing rounds already closing in the first months of 2026[1], a sign that capital is rotating toward clinical-stage companies with validated science.

Mar 19, 2026 07:00 AM • globenewswire.com

Avoro Capital Advisors LLC Takes $4.58 Million Position in Tango Therapeutics, Inc. $TNGX

Avoro Capital Advisors LLC acquired a new stake in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 545,000 shares of the company's stock, valued at approximately $4,578,000. Avoro Capital Advisors LLC owned approximately

Mar 13, 2026 11:07 PM • defenseworld.net

X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention

Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage initiations and maintained Buy-equivalent ratings from institutional research desks ahead of 2026 clinical catalysts.

Mar 09, 2026 07:15 AM • 247wallst.com

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $15.86 Average Target Price from Brokerages

Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to

Mar 08, 2026 10:01 PM • defenseworld.net

Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise

Tango Therapeutics, Inc. is downgraded to Hold after a sharp rally, with 2026 positioned as a pivotal, data-driven year. Vopimetostat, the lead PRMT5 inhibitor, advances to a pivotal trial in 2L MTAP-deleted pancreatic cancer, with FDA-aligned design and robust enrollment. TNGX boasts a $343m cash position, partnerships with Gilead and Revolution Medicines, and multiple upcoming data catalysts, but faces fierce competition.

Mar 06, 2026 11:02 AM • seekingalpha.com

TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS

Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.

Mar 06, 2026 05:46 AM • zacks.com

Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca.

Mar 05, 2026 09:17 AM • investors.com

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing

Purchased 1,104,734 shares of Tango Therapeutics; estimated trade size $9.52 million based on quarterly average pricing Quarter-end position value increased by $14.28 million, reflecting both trading and stock price changes Added stake equivalent to 2.08% of 13F reportable assets under management (AUM) Post-trade, fund holds 10,876,219 shares valued at $96.36 million Position now represents 21.09% of fund AUM, which makes it the fund's n/a largest holding

Mar 04, 2026 01:15 PM • fool.com

Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells $693,985.65 in Stock

Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) insider Adam Crystal sold 54,345 shares of the firm's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $12.77, for a total value of $693,985.65. Following the transaction, the insider owned 132,873 shares in the company, valued at approximately

Mar 02, 2026 12:03 AM • defenseworld.net

Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat

Tango Therapeutics (NASDAQ: TNGX) is preparing to move further into late-stage development for its PRMT5 inhibitor vopimetostat, newly appointed CEO Malte Peters said during a Guggenheim fireside chat. Peters, who has served on Tango's board since 2018, told attendees the company should not expect a "drastic strategic change" following his transition into the CEO role. Peters

Feb 16, 2026 09:03 PM • defenseworld.net

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026 09:46 AM • seekingalpha.com

Tango Therapeutics price target raised to $30 from $20 at Mizuho

$30.00 (was $24.87)

Joseph Catanzaro · Mizuho Securities

May 15, 2026 07:00 AM • TheFly

Piper Sandler cuts Tango Therapeutics Neutral following Q1 report

$24.00 (was $24.87)

Piper Sandler

May 14, 2026 05:36 PM • TheFly

Tango Therapeutics price target raised to $55 from $28 at Leerink

$55.00 (was $24.87)

UBS

May 14, 2026 02:47 PM • TheFly

Tango Therapeutics price target raised to $33 from $19 at Wedbush

$33.00 (was $23.98)

Wedbush

May 14, 2026 08:17 AM • TheFly

Tango Therapeutics downgraded to Hold from Buy at Jefferies

$27.00 (was $25.51)

Maury Raycroft · Jefferies

May 14, 2026 05:04 AM • TheFly

Tango Therapeutics price target raised to $40 from $24 at Stifel

$40.00 (was $25.75)

Stifel Nicolaus

Apr 27, 2026 06:46 AM • TheFly

Tango Therapeutics price target raised to $24 from $15 at Stifel

$24.00 (was $16.45)

Laura Prendergast · Stifel Nicolaus

Mar 09, 2026 07:14 AM • TheFly

Tango Therapeutics Inc. (TNGX) PT Raised to $18 at Jefferies

$18.00 (was $16.83)

Maury Raycroft · Jefferies

Mar 05, 2026 04:46 PM • StreetInsider

Tango Therapeutics initiated with an Outperform at Mizuho

$19.00 (was $12.20)

Mizuho Securities

Feb 23, 2026 07:28 AM • TheFly

Tango Therapeutics price target raised to $14 from $11 at Piper Sandler

$14.00 (was $11.69)

Piper Sandler

Jan 16, 2026 06:56 AM • TheFly

Tango Therapeutics initiated with a Buy at Stifel

$15.00 (was $9.57)

Stifel Nicolaus

Dec 03, 2025 04:19 PM • TheFly

Tango Therapeutics price target raised to $12 from $10 at Guggenheim

$12.00 (was $7.85)

Michael Schmidt · Guggenheim

Oct 24, 2025 06:49 AM • TheFly

Piper Sandler Reiterates Overweight Rating on Tango Therapeutics Inc. (TNGX)

$18.00 (was $8.97)

Joseph Catanzaro · Piper Sandler

Sep 17, 2024 03:20 AM • StreetInsider

Tango Therapeutics price target raised to $13 from $11 at Wedbush

$13.00 (was $8.72)

Robert Driscoll · Wedbush

Aug 08, 2024 04:21 AM • TheFly

Tango Therapeutics price target lowered to $13 from $16 at H.C. Wainwright

$13.00 (was $6.91)

Robert Burns · H.C. Wainwright

May 28, 2024 02:07 AM • TheFly